Tobin Schilke - Jun 1, 2023 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Jun 1, 2023
Transactions value $
-$98,070
Form type
4
Date filed
6/5/2023, 06:06 PM
Previous filing
May 2, 2023
Next filing
Jul 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Sale -$82.6K -2.7K -3.21% $30.57 81.3K Jun 1, 2023 Direct F1
transaction RVNC Common Stock Sale -$15.5K -500 -0.61% $31.00 80.8K Jun 2, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke.